| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/14/2005 | EP1572872A2 Igs as modifiers of the p53 pathway and methods of use |
| 09/14/2005 | EP1572869A2 Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof |
| 09/14/2005 | EP1572868A2 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 09/14/2005 | EP1572748A1 Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| 09/14/2005 | EP1572243A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent |
| 09/14/2005 | EP1572235A2 Methods of therapy and diagnosis using targeting of cells that express lax |
| 09/14/2005 | EP1572170A2 Immunotoxin as a therapeutic agent and uses thereof |
| 09/14/2005 | EP1572124A2 Hcv e1e2 vaccine compositions |
| 09/14/2005 | EP1572122A2 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
| 09/14/2005 | EP1572102A2 Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| 09/14/2005 | EP1572100A2 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
| 09/14/2005 | EP1572082A2 Cancer-linked gene as target for chemotherapy |
| 09/14/2005 | EP1572074A2 Stabilized synthetic immunogen delivery system |
| 09/14/2005 | EP1572073A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 09/14/2005 | EP1572072A2 Methods of treating infection by drug resistant bacteria |
| 09/14/2005 | EP1572066A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2 |
| 09/14/2005 | EP1572064A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 09/14/2005 | EP1571910A2 Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| 09/14/2005 | EP1438060A4 Prevention and treatment of restenosis by local administration of drug |
| 09/14/2005 | EP1082141B1 Cd40 binding antibodies and ctl peptides for treating tumors |
| 09/14/2005 | EP1066395B1 Inducible alphaviral gene expression system |
| 09/14/2005 | EP1013665B1 Polypeptide having water channel activity and dna sequence |
| 09/14/2005 | CN1668762A Sgk and Nedd used as diagnostic and therapeutic targets |
| 09/14/2005 | CN1668758A Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| 09/14/2005 | CN1668754A Carotene synthase gene and uses therefor |
| 09/14/2005 | CN1668751A Modified adenovirus vectors for use in vaccines and gene therapy |
| 09/14/2005 | CN1668750A Her-2/neu DNA vaccine having anti-cancer activity |
| 09/14/2005 | CN1668746A MUC-1 antigen with reduced number of VNTR repeat units |
| 09/14/2005 | CN1668736A GM-negative EHV-mutants without heterologous elements |
| 09/14/2005 | CN1668733A Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 09/14/2005 | CN1668629A Modulation of the expression of genes dependent on STAT-1 |
| 09/14/2005 | CN1668359A Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
| 09/14/2005 | CN1668337A Agents for gene therapeutic for cerebrovascular disorders |
| 09/14/2005 | CN1667416A Diagnostics and therapeutics for glaucoma |
| 09/14/2005 | CN1667124A Recombinant adenovirus and its application in malignant tumor treatment |
| 09/14/2005 | CN1667120A RNA interfered target sequence of HBV and use thereof |
| 09/14/2005 | CN1666780A Method for degrading AML 1-ETO fusion protein and used reagent |
| 09/14/2005 | CN1219055C A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 09/13/2005 | US6943246 3′terminal sequence of hepatitis C virus genome and diagnostic and therapeutic uses thereof |
| 09/13/2005 | US6943243 Control of gene expression in eukaryotic cells |
| 09/13/2005 | US6943240 Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
| 09/13/2005 | US6943238 Antibodies to cyclin E2 protein |
| 09/13/2005 | US6943236 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 09/13/2005 | US6943153 administering genetic engineered adeno-associated virus as angiogenesis inhibitors for prophylaxis of vision defects |
| 09/13/2005 | US6943152 DNA vaccine-PCV |
| 09/13/2005 | US6943151 Method of inhibiting bone resorption and/or promoting bone formation using GLP-2 and related compounds |
| 09/13/2005 | US6943150 Antiapoptosis polypeptides or fusion proteins coded by nucleic acids |
| 09/13/2005 | US6943027 Contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining product with an amphiphilic cationic lipid; increased shelf life and high transfection activity |
| 09/13/2005 | US6943026 A mixture of first and second nucleic acid constructs, is used for gene therapy, as antitumor agents, antiproliferative agents, suppressed by a wild-type p53 allele in non-tumour cells relative to tumor cells, prodrug activating thymidine kinase |
| 09/13/2005 | US6943022 Inhibition of apoptosis by the expression of antisense RNA of caspase-3 |
| 09/13/2005 | US6943018 Transgenic expression from a SOCS-3 promoter in vertebrate cells |
| 09/13/2005 | US6943016 incubating a mixture of astrocytes and glial cells from patient surgical resection, culturing, astrocytes joining to the culture vessel, removing the un-attached cells; purification; treating CNS trauma, neurodegenerative disorders |
| 09/13/2005 | US6943015 Large scale production of packaged alphavirus replicons |
| 09/13/2005 | US6943014 Invention provides cDNAs encoding deoxyribonuclease II beta and isolated, purified deoxyribonuclease II beta proteins and antibodies against this protein and antisense agents targeted to cDNA or mRNA encoding deoxyribonuclease II beta |
| 09/13/2005 | US6943013 DNA expression vector; host cell transformed, transfected or infected with the vector; transgenic cell, tissue or organism; HCDS1 protein |
| 09/13/2005 | US6943000 Detection of modulator of enzyme activity; obtain cells, incubate with modulator, monitor adjustment in enzyme activity, adjustment in activity indicates modulator |
| 09/13/2005 | US6942992 Nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 09/13/2005 | US6942983 An isolated monoclonal antibody is used for binding and detecting a polypeptide having amino acid sequence with valine at residue 835, modulate kinase activity in cells, protein kinase C |
| 09/13/2005 | US6942982 FEBP1 protein vector host cells and method for making FEBP1 protein |
| 09/13/2005 | US6942981 Method of determining interactions with PDZ-domain polypeptides |
| 09/13/2005 | US6942979 Method for screening substances capable of modulating the activity of a TRAAK potassium channel |
| 09/13/2005 | US6942978 Diagnosing cancer by detecting a TADG-12 protein in biological sample, immunoaffinity to an antibody, bioassay, immunoassay |
| 09/13/2005 | US6942864 use of live, recombinant leporipox virus comprising exogenous DNA, which is operably linked to at least one expression control element and which is incorporated into non-essential region of virus genome, in manufacture of vector vaccine |
| 09/13/2005 | US6942855 recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA; use in genetic vaccines for example |
| 09/13/2005 | US6942853 Latent fusion protein |
| 09/09/2005 | WO2005083126A2 Alterations of fibulin genes in macular degeneration |
| 09/09/2005 | WO2005083124A1 Antisense oligonucleotide modulation of stat3 expression |
| 09/09/2005 | WO2005083085A1 Treatment of hyperproliferative disease |
| 09/09/2005 | WO2005083076A1 Immune stimulant oligonucleotide inducing interferon alpha |
| 09/09/2005 | WO2005083075A1 Novel gene participating in epidermal differentiation and use thereof |
| 09/09/2005 | WO2005083074A1 Tumor antigen peptides |
| 09/09/2005 | WO2005083071A1 Polynucleotide participating in rheumatoid arthritis and utilization of the same |
| 09/09/2005 | WO2005083070A1 Pharmaceutical composition for lowering blood sugar level |
| 09/09/2005 | WO2005082921A1 Method for inhibiting cellular proliferation |
| 09/09/2005 | WO2005082422A1 Combination of ad-p53 and chemotherapy for the treatment of tumours |
| 09/09/2005 | WO2005082415A2 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| 09/09/2005 | WO2005082396A2 Use of mda-7 to inhibit infection by pathogenic organisms |
| 09/09/2005 | WO2005082080A2 Method to modulate the immune system with a novel guanine nucleotide exchange factor |
| 09/09/2005 | WO2005082070A2 Compositions and methods for the systemic treatment of arthritis |
| 09/09/2005 | WO2005081847A2 Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
| 09/09/2005 | WO2005065722A3 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation |
| 09/09/2005 | WO2005046614A3 System for treating and preventing breast cancer |
| 09/09/2005 | WO2005046611A3 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 09/09/2005 | WO2005042714A3 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| 09/09/2005 | WO2005027979A3 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 09/09/2005 | WO2005026362A3 Lymphatic and blood endothelial cell genes |
| 09/09/2005 | WO2005000220A8 Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| 09/09/2005 | WO2004089189B1 Minimally-invasive imaging of viral gene therapy and presurgical applications thereof |
| 09/09/2005 | WO2004087862A3 Tak1-mediated inhibition of osteogenesis |
| 09/09/2005 | WO2004076635A3 Therapeutic applications of thrombomodulin gene via viral and non-viral vectors |
| 09/09/2005 | WO2004067745A8 Gene expression inducing fusion protein and method for controlling gene expression induction |
| 09/09/2005 | WO2004061113A8 Adeno-associated virus mediated b7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers |
| 09/09/2005 | WO2003057854A3 Novel proteins and nucleic acids encoding same |
| 09/09/2005 | CA2557508A1 Compositions and methods for the systemic treatment of arthritis |
| 09/09/2005 | CA2557499A1 Il-13 mutein proteins, antibodies, compositions, methods and uses |
| 09/09/2005 | CA2557326A1 Combination of ad-p53 and chemotherapy for the treatment of tumours |
| 09/09/2005 | CA2556632A1 Egf receptor epitope peptides and uses thereof |
| 09/09/2005 | CA2555245A1 Antisense oligonucleotide modulation of stat3 expression |
| 09/09/2005 | CA2555105A1 Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
| 09/09/2005 | CA2548220A1 Use of mda-7 to inhibit infection by pathogenic organisms |